Correlation Between Polar Capital and Faron Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Polar Capital and Faron Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Polar Capital and Faron Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Polar Capital Technology and Faron Pharmaceuticals Oy, you can compare the effects of market volatilities on Polar Capital and Faron Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Polar Capital with a short position of Faron Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Polar Capital and Faron Pharmaceuticals.

Diversification Opportunities for Polar Capital and Faron Pharmaceuticals

-0.71
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Polar and Faron is -0.71. Overlapping area represents the amount of risk that can be diversified away by holding Polar Capital Technology and Faron Pharmaceuticals Oy in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Faron Pharmaceuticals and Polar Capital is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Polar Capital Technology are associated (or correlated) with Faron Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Faron Pharmaceuticals has no effect on the direction of Polar Capital i.e., Polar Capital and Faron Pharmaceuticals go up and down completely randomly.

Pair Corralation between Polar Capital and Faron Pharmaceuticals

Assuming the 90 days trading horizon Polar Capital Technology is expected to generate 0.32 times more return on investment than Faron Pharmaceuticals. However, Polar Capital Technology is 3.09 times less risky than Faron Pharmaceuticals. It trades about 0.21 of its potential returns per unit of risk. Faron Pharmaceuticals Oy is currently generating about -0.09 per unit of risk. If you would invest  29,800  in Polar Capital Technology on September 25, 2024 and sell it today you would earn a total of  5,100  from holding Polar Capital Technology or generate 17.11% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Polar Capital Technology  vs.  Faron Pharmaceuticals Oy

 Performance 
       Timeline  
Polar Capital Technology 

Risk-Adjusted Performance

16 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Polar Capital Technology are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady technical and fundamental indicators, Polar Capital exhibited solid returns over the last few months and may actually be approaching a breakup point.
Faron Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Faron Pharmaceuticals Oy has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Polar Capital and Faron Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Polar Capital and Faron Pharmaceuticals

The main advantage of trading using opposite Polar Capital and Faron Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Polar Capital position performs unexpectedly, Faron Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Faron Pharmaceuticals will offset losses from the drop in Faron Pharmaceuticals' long position.
The idea behind Polar Capital Technology and Faron Pharmaceuticals Oy pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Other Complementary Tools

Transaction History
View history of all your transactions and understand their impact on performance
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Technical Analysis
Check basic technical indicators and analysis based on most latest market data